About Aduro BioTech (NASDAQ:ADRO)
Aduro BioTech, Inc., an immunotherapy company, focuses on the discovery, development, and commercialization of therapies that transform the treatment of challenging diseases. The company is developing ADU-S100, which is in Phase I monotherapy study, as well as in Phase 1b combination study with an anti-PD1 immune checkpoint inhibitor; ADU-214 that is in Phase I clinical trials for the treatment of lung cancer; and ADU-741 for the treatment of prostate cancer. Its products pipeline also comprises BION-1301, a B-select monoclonal antibody novel therapy for multiple myeloma; A PRoliferation-Inducing Ligand for the treatment of multiple myeloma, chronic lymphocytic leukemia, and colorectal carcinoma; CD27, a co-stimulatory receptor for the treatment of cancer; and CTLA-4 for the treatment of advanced melanoma and other cancers. The company's pLADD program is based on proprietary attenuated strains of Listeria that have been engineered to express tumor neo antigens that are specific to an individual patient's tumor. It has collaboration agreements with Novartis Pharmaceuticals Corporation, Janssen Biotech, Inc, and Merck. The company was formerly known as Oncologic, Inc. and changed its name to Aduro BioTech, Inc. in June 2008. Aduro BioTech, Inc. was founded in 2000 and is based in Berkeley, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ADRO
CUSIPN/A
Phone510-848-4400
Debt
Debt-to-Equity RatioN/A
Current Ratio9.10
Quick Ratio9.10
Price-To-Earnings
Trailing P/E Ratio-5.77
Forward P/E Ratio-6.51
P/E GrowthN/A
Sales & Book Value
Annual Sales$17.24 million
Price / Sales37.45
Cash FlowN/A
Price / CashN/A
Book Value$3.07 per share
Price / Book2.67
Profitability
EPS (Most Recent Fiscal Year)($1.42)
Net Income$-91,860,000.00
Net Margins-455.58%
Return on Equity-39.00%
Return on Assets-20.59%
Miscellaneous
Employees162
Outstanding Shares78,730,000
Aduro BioTech (NASDAQ:ADRO) Frequently Asked Questions
What is Aduro BioTech's stock symbol?
Aduro BioTech trades on the NASDAQ under the ticker symbol "ADRO."
How were Aduro BioTech's earnings last quarter?
Aduro BioTech Inc (NASDAQ:ADRO) released its quarterly earnings data on Wednesday, May, 2nd. The biotechnology company reported ($0.28) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.35) by $0.07. The biotechnology company had revenue of $6.63 million for the quarter, compared to the consensus estimate of $3.88 million. Aduro BioTech had a negative net margin of 455.58% and a negative return on equity of 39.00%. View Aduro BioTech's Earnings History.
What price target have analysts set for ADRO?
7 brokers have issued 12-month target prices for Aduro BioTech's shares. Their forecasts range from $8.00 to $30.00. On average, they expect Aduro BioTech's stock price to reach $15.20 in the next twelve months. View Analyst Ratings for Aduro BioTech.
What are Wall Street analysts saying about Aduro BioTech stock?
Here are some recent quotes from research analysts about Aduro BioTech stock:
- 1. According to Zacks Investment Research, "Aduro reported narrower-than-expected loss in the fourth quarter of 2017 while revenues missed estimates. The company has a broad, promising pipeline of novel immunotherapies under development for treatment of a variety of cancers. The company’s collaboration agreements with large pharma companies — Novartis and Johnson & Johnson — not only validate the company’s research platforms but also enhance its financial position, providing it with adequate funds. However, with no approved products in Aduro’s portfolio, the company heavily depends on funds generated from collaboration and license agreements, government grants as well as other payments for the development of its pipeline candidates. Thus, an inability to secure sufficient funding could hinder Aduro’s pipeline progress. Shares of the company have underperformed the industry in a year’s time." (3/7/2018)
- 2. Cantor Fitzgerald analysts commented, "ADRO shares are trading up modestly on the disclosure of a $3 million milestone from MRK’s (Merck, NC) initiation of a Phase I trial with the anti- CD27 candidate." (3/5/2018)
- 3. HC Wainwright analysts commented, "All Three Platforms Now Clinical Stage; We Have High Expectations for B-Select Platform B-select investment starts bearing clinical stage candidates. Aduro announced the expected initiation of a Phase 1/2 clinical trial with its anti-APRIL antibody, BION-1301. This two part, open-label study, is being conducted in relapsed or refractory multiple myeloma patients (at least three prior systemic therapies). Once the recommended Phase 2 dose is identified in part 1, patients are to be expanded at the selected dose with the primary endpoint of overall response rate. The APRIL/BCMA pathway was also a hot topic at the recent ASH conference as an encouraging new target against myeloma. A proliferation inducing ligand (APRIL) is one of the main high affinity ligands that binds and activates BCMA resulting in a pro-survival cell signal. APRIL is a member of the TNF family and is overexpressed in patients with multiple myeloma (MM)." (12/13/2017)
Who are some of Aduro BioTech's key competitors?
Some companies that are related to Aduro BioTech include OPKO Health (OPK), Intercept Pharmaceuticals (ICPT), Arena Pharmaceuticals (ARNA), Clovis Oncology (CLVS), Xencor (XNCR), Corcept Therapeutics (CORT), Enanta Pharmaceuticals (ENTA), TESARO (TSRO), Heron Therapeutics (HRTX), Akcea Therapeutics (AKCA), Spectrum Pharmaceuticals (SPPI), Global Blood Therapeutics (GBT), Puma Biotechnology (PBYI), Insmed (INSM) and Endo International (ENDP).
Who are Aduro BioTech's key executives?
Aduro BioTech's management team includes the folowing people:
- Mr. Stephen T. Isaacs, Chairman, Pres & CEO (Age 69)
- Mr. Blaine E. Templeman, Chief Legal Officer & Sec. (Age 52)
- Dr. Natalie R. Sacks M.D., Chief Medical Officer (Age 53)
- Ms. Jennifer Lew, Chief Financial Officer (Age 45)
- Mr. Gregory W. Schafer, Consultant (Age 54)
When did Aduro BioTech IPO?
(ADRO) raised $119 million in an initial public offering (IPO) on Wednesday, April 15th 2015. The company issued 7,000,000 shares at $17.00 per share. BofA Merrill Lynch and Leerink Partners acted as the underwriters for the IPO and William Blair and Canaccord Genuity were co-managers.
Has Aduro BioTech been receiving favorable news coverage?
Press coverage about ADRO stock has been trending somewhat positive recently, Accern Sentiment reports. Accern rates the sentiment of press coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Aduro BioTech earned a daily sentiment score of 0.08 on Accern's scale. They also gave news coverage about the biotechnology company an impact score of 47.03 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the next few days.
Who are Aduro BioTech's major shareholders?
Aduro BioTech's stock is owned by many different of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (4.51%), Point72 Asset Management L.P. (2.16%), Baillie Gifford & Co. (2.10%), Harvard Management Co. Inc. (1.87%), Millennium Management LLC (1.63%) and BVF Inc. IL (1.03%). Company insiders that own Aduro BioTech stock include Blaine Templeman, Dirk G Brockstedt, Elsas Andrea Van, Gregory W Schafer, Jennifer Lew, Ross Haghighat, Stephen T Isaacs and Thomas W Dubensky. View Institutional Ownership Trends for Aduro BioTech.
Which institutional investors are selling Aduro BioTech stock?
ADRO stock was sold by a variety of institutional investors in the last quarter, including Harvard Management Co. Inc., Point72 Asset Management L.P., Oak Ridge Investments LLC, BlackRock Inc., Wells Fargo & Company MN and JPMorgan Chase & Co.. Company insiders that have sold Aduro BioTech company stock in the last year include Blaine Templeman, Dirk G Brockstedt, Elsas Andrea Van, Gregory W Schafer, Jennifer Lew, Stephen T Isaacs and Thomas W Dubensky. View Insider Buying and Selling for Aduro BioTech.
Which institutional investors are buying Aduro BioTech stock?
ADRO stock was bought by a variety of institutional investors in the last quarter, including Millennium Management LLC, BVF Inc. IL, Baillie Gifford & Co., Artal Group S.A., Barclays PLC, Foundry Partners LLC, Quantitative Systematic Strategies LLC and Alps Advisors Inc.. View Insider Buying and Selling for Aduro BioTech.
How do I buy shares of Aduro BioTech?
Shares of ADRO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Aduro BioTech's stock price today?
One share of ADRO stock can currently be purchased for approximately $8.20.
How big of a company is Aduro BioTech?
Aduro BioTech has a market capitalization of $621.97 million and generates $17.24 million in revenue each year. The biotechnology company earns $-91,860,000.00 in net income (profit) each year or ($1.42) on an earnings per share basis. Aduro BioTech employs 162 workers across the globe.
How can I contact Aduro BioTech?
Aduro BioTech's mailing address is 740 HEINZ AVENUE, BERKELEY CA, 94710. The biotechnology company can be reached via phone at 510-848-4400 or via email at [email protected]
MarketBeat Community Rating for Aduro BioTech (ADRO)
MarketBeat's community ratings are surveys of what our community members think about Aduro BioTech and other stocks. Vote "Outperform" if you believe ADRO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ADRO will underperform the S&P 500 over the long term. You may vote once every thirty days.
